Oramed Pharmaceuticals Inc (NASDAQ:ORMP) Quarterly Sentiment Report

June 24, 2018 - By Vivian Currie

Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) Logo

Sentiment for Oramed Pharmaceuticals Inc (NASDAQ:ORMP)

Oramed Pharmaceuticals Inc (NASDAQ:ORMP) institutional sentiment decreased to 0.33 in 2018 Q1. Its down -2.42, from 2.75 in 2017Q4. The ratio dived, as 3 active investment managers opened new or increased equity positions, while 9 sold and reduced equity positions in Oramed Pharmaceuticals Inc. The active investment managers in our partner’s database now possess: 234,885 shares, down from 329,110 shares in 2017Q4. Also, the number of active investment managers holding Oramed Pharmaceuticals Inc in their top 10 equity positions was flat from 0 to 0 for the same number . Sold All: 5 Reduced: 4 Increased: 1 New Position: 2.

Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the use of orally ingestible capsules or pills for delivery of polypeptides. The company has market cap of $110.78 million. The Company’s product portfolio includes ORMD-0801, an oral insulin capsule, which has completed Phase IIb clinical trials for the treatment of diabetes; and ORMD-0901, an analog for GLP-1 gastrointestinal hormone, which has completed Phase Ib clinical trials for the treatment of type 2 diabetes. It currently has negative earnings. The firm operates primarily in Israel.

The stock increased 2.40% or $0.18 during the last trading session, reaching $7.67. About 22,670 shares traded. Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) has declined 10.31% since June 24, 2017 and is downtrending. It has underperformed by 22.88% the S&P500.

Analysts await Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) to report earnings on July, 5. They expect $-0.32 earnings per share, down 113.33 % or $0.17 from last year’s $-0.15 per share. After $-0.20 actual earnings per share reported by Oramed Pharmaceuticals Inc. for the previous quarter, Wall Street now forecasts 60.00 % negative EPS growth.

Bank Of America Corp De holds 0% of its portfolio in Oramed Pharmaceuticals Inc. for 1,117 shares. Bank Of Montreal Can owns 2,600 shares or 0% of their US portfolio. Moreover, Barclays Plc has 0% invested in the company for 41,186 shares. The New York-based Citigroup Inc has invested 0% in the stock. Deutsche Bank Ag, a Germany-based fund reported 24,919 shares.

More recent Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) news were published by: Benzinga.com which released: “41 Biggest Movers From Yesterday” on May 31, 2018. Also Prnewswire.com published the news titled: “Oramed to Present at the American Diabetes Association 78th Scientific Sessions” on June 12, 2018. Prnewswire.com‘s news article titled: “Oramed Patent Allowed in the US for Oral Administration of Proteins” with publication date: May 30, 2018 was also an interesting one.

Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: